

## Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A

Daniel P. Hart,<sup>1,2</sup> Nazmiye Uzun,<sup>3</sup> Stuart Skelton,<sup>1,3</sup> Alison Kakoschke,<sup>3</sup> Jacob Househam,<sup>3</sup> David S. Moss<sup>3</sup> and Adrian J. Shepherd<sup>3</sup>

<sup>1</sup>Blizard Institute, Barts and The London School of Medicine and Dentistry, QMUL, London; <sup>2</sup>The Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London; <sup>3</sup>Department of Biological Sciences and Institute of Structural and Molecular Biology, Birkbeck, University of London, UK

©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2018.195669

Received: April 20, 2018.

Accepted: September 27, 2018.

Pre-published: September 28, 2018.

Correspondence: *ADRIAN J. SHEPHERD*

a.shepherd@mail.cryst.bbk.ac.uk

---

## Supplemental Information

**Supplemental Table S1.** Breakdown of calculations required to identify novel peptide-MHC surfaces.

Description	Count	Calculation	Total
<b>Step 1: calculations required for a single residue</b>			
15-mers spanning residue	15		15
Positions 15-mer can bind to MHC	7	$15 \times 7$	105
HLA alleles	25	$105 \times 25$	2,625
<b>Step 2: calculations required for endogenous FVIII (using total from step 1)</b>			
Reported F8 missense mutations	956	$2,625 \times 956$	2,509,500
<b>Step 3: calculations required for tFVIII (using total from step 1)</b>			
Locations associated with F8 mutations	605	$2,625 \times 605$	1,588,125
<b>Step 4: summation</b>			
Sum totals from <b>step 2</b> and <b>step 3</b>		$2,509,500 + 1,588,125$	4,097,625
<b>Step 5: proteome scanning</b>			
Two different types of calculation are required: a) matching 9-mer cores of risk-associated peptides (from <b>step 4</b> ) to proteome 9-mers (see Figure 4A); and b) calculating the MHC binding cores and binding strengths of matched peptides (see Figure 4B). We do not keep track of the exact number of calculations performed, so here we estimate the lower bounds.			
<b>a) Proteome matching:</b>			
Risk-associated peptides	$\gg 12,189$		
Non-identical proteome 9-mers	11,272,502	$12,189 \times 11,272,502$	137,400,526,878
<b>b) MHC binding:</b>			
F8 mutation/HLA allele combinations with reduced risk after scanning	4,302		
Rough estimate of ratio of non-binders to binders	10	$4,302 \times 10$	43,020

Note that the number of calculations at step 2 is higher than the number at step 3 because a single location may be associated with more than one reported missense mutation, e.g. K48E, K48T and K48N.


**Supplemental Table S2.** Percentage of risk-associated F8 missense mutations for different HLA alleles, before and after proteome scanning




HLA allele	risk (%) with 1000 nM threshold		risk (%) with 500 nM threshold	
	before	after	before	after
DRB1*01:01	86	48	78	41
DRB1*03:01	34	25	24	16
DRB1*04:01	62	38	47	25
DRB1*04:04	66	38	53	26
DRB1*04:05	60	35	49	28
DRB1*07:01	70	46	60	39
DRB1*08:02	36	23	16	10
DRB1*09:01	66	41	50	25
DRB1*11:01	58	37	43	24
DRB1*13:02	34	25	26	16
DRB1*15:01	64	36	49	25
DRB3*01:01	35	25	24	17
DRB4*01:01	60	33	39	16
DRB5*01:01	58	40	48	31
DPA1*01-DPB1*04:01	41	27	33	23
DPA1*01:03-DPB1*02:01	46	29	36	21
DPA1*02:01-DPB1*01:01	59	34	47	25
DPA1*02:01-DPB1*05:01	30	18	17	8
DPA1*03:01-DPB1*04:02	52	33	41	22
DQA1*01:01-DQB1*05:01	27	21	19	15
DQA1*01:02-DQB1*06:02	54	34	36	20
DQA1*03:01-DQB1*03:02	21	15	10	6
DQA1*04:01-DQB1*04:02	21	13	11	6
DQA1*05:01-DQB1*02:01	36	18	24	12
DQA1*05:01-DQB1*03:01	58	32	40	20

**Supplemental Figure S1.** MHC-binding strengths of *F8* peptides predicted to form novel pMHC surfaces with and without proteome scanning.




Heatmap showing the predicted occurrence of novel pMHC surfaces and binding strengths for 25 HLA-DR/DP/DQ alleles (*y* axis) covering the complete set of missense mutations in the Factor VIII Gene (*F8*) Variant Database (*x* axis). Black and grey squares indicate *F8* missense mutation/HLA allele combinations that are not predicted to form a novel pMHC surface. Otherwise the temperature color scale indicates the predicted binding strength of the strongest binding peptide with a novel pMHC surface for each remaining *F8* missense mutation/HLA allele combination. (A) MHC-binding strengths of *F8* peptides predicted to form novel pMHC surfaces without proteome scanning. (B) MHC-binding strengths of *F8* peptides predicted to form novel pMHC surfaces with proteome scanning. Grey squares indicate *F8* missense mutation/HLA allele combinations that are no longer predicted to form a novel pMHC surface after cross-matches to the proteome are taken into account.




**A**
























**B**

